Current Report Filing (8-k)
January 14 2022 - 05:14PM
Edgar (US Regulatory)
0001535955 false 0001535955 2022-01-14
2022-01-14 iso4217:USD xbrli:shares iso4217:USD xbrli:shares
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of
The
Securities Exchange Act of 1934
Date
of Report (Date of Earliest Event Reported):
January 14, 2022
LIPOCINE INC.
(Exact name of registrant as specified in its
charter)
Commission
File No.
001-36357
|
Delaware |
|
99-0370688 |
(State
or other jurisdiction
of incorporation) |
|
(IRS
Employer
Identification Number) |
675 Arapeen Drive,
Suite 202
Salt Lake City,
Utah
84108
(Address
of principal executive offices) (Zip Code)
Registrant’s
telephone number, including area code:
(801)
994-7383
Former
name or former address, if changed since last report: Not
Applicable
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
|
☐ |
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425) |
| |
|
|
☐ |
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b)) |
| |
|
|
☐ |
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c)) |
I
Securities registered pursuant to Section 12(b) of the
Act:
|
Title
of each class |
|
Trading
Symbol(s) |
|
Name
of each exchange on which registered |
|
Common Stock, par value $0.0001 per share |
|
LPCN |
|
The
NASDAQ Stock Market LLC |
Indicate by
check mark whether the registrant is an emerging growth company as
defined in Rule 405 of the Securities Act of 1933 (17 CFR §
230.405) or Rule 12b-2 of the Securities Exchange Act of
1934 (17 CFR § 240.12b-2).
Emerging
growth company
☐
If an
emerging growth company, indicate by check mark if the registrant
has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided
pursuant to Section 13(a) of the Exchange Act. ☐
Item
3.01 Notice of Delisting or
Failure to Satisfy a Continued Listing Rule or Standard; Transfer
of Listing.
On January
14, 2022, Lipocine Inc. (“Lipocine”) received written notice
from the staff (the “Staff”) of the Listing Qualifications
Department of The Nasdaq Stock Market (“Nasdaq”)
indicating the Company is no
longer in compliance with Nasdaq Listing Rules set forth in Listing
Rule 5605, which requires a majority independent board, audit
committee and compensation committee. Pursuant to Nasdaq Listing
Rules 5605(b)(1)(A), 5605(c)(4) and 5605(d)(4), the Company is
entitled to a cure period to regain compliance with Nasdaq Listing
requirements, which cure period will expire at the earlier of the
Company’s 2022 annual meeting of stockholders (the “2022 Annual
Meeting”) or June 6, 2022. The Company intends to appoint an
additional independent director to the board of directors, audit
committee and compensation committee prior to the end of the cure
period.
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
| |
|
|
LIPOCINE
INC. |
|
|
|
|
|
|
| Date: |
January
14, 2022 |
|
By: |
/s/
Mahesh V. Patel |
| |
|
|
|
Mahesh
V. Patel |
| |
|
|
|
President
and Chief Executive Officer |
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Jul 2022 to Aug 2022
Lipocine (NASDAQ:LPCN)
Historical Stock Chart
From Aug 2021 to Aug 2022
